Game-changing Alzheimer's drugs could drive a wave of ...

Recent breakthroughs in Alzheimer's treatment, notably lecanemab's FDA approval and donanemab's Phase 3 trial success, offer new hope for patients and investment opportunities. Despite challenges in access and infrastructure, these developments mark a significant step forward in combating Alzheimer's, promising better outcomes and reducing healthcare burdens.